Malaysian Organisation of pharmaceutical Industries (MOPI) as started by eight manufacturers, which were local, foreign and joint venture companies.

MOPI was incorporated on 6 March 1981 as a company limited by guarantee. Raja Zainal Abidin bin Raja Haji Takchik of Raza Manufacturing Sdn Bhd was MOPI's first president.
MOPI's membership is restricted manufacturers with factories in Malaysia that are licensed by the drug Control Authority, Ministry of health, to manufacture pharmaceuticals.
MOPI's original membership of eight has grown to the current 34. All major pharmaceutical manufacturers in the country are members of MOPI.

Main Activities:
MOPI, in co-operation with the government and other bodies, represent the interests of the pharmaceutical industry.

Promotion and development of the industry

Foster closer co-operation among members of the Industry.

Facilitate and encourage the development, exchange and transfer of information and technology, domestically and internationally.

Promote and facilitate orderly trade in life science products.

MOPI's Strategic Role:
The MOPI membership collectively reduces about 35 percent of Malaysia's medicine requirement. In terms of product range, MOPI members have the capabilities to manufacture more than 80 percent of the product categories in the National Essential Drugs List of Malaysia.

To a large extent, MOPI's existence has been a medium and catalyst for the rapid development and capitalisation of the local pharmaceutical industry during the last decade.

It has evolved into a modern, sophisticated sector of the Malaysian economy, and it is capable of producing a wide range of products in compliance with the WHO Code of Good Manufacturing Practice and internationally accepted pharmacopoeia standards.

MOPI has also taken on the role of training personnel in the industry in the latest technologies evolving in the industry, including training in validation procedures for processes as well as equipment and also in current Good Manufacturing Practice according to the European (PIC) Code as Malaysia is expected to be a member of the PIC/S soon.

Having invested in the high-technology machineries and equipment and formalized training, MOPI members now have the capability to manufacture a wide range of products including large and small injectables, novel drug delivery systems, high technology testing and analytical equipment to met inter-nationally accepted standards of quality assurance.

Research and development is an-other key area for the MOPI membership. The focus areas are product development, formulation improvement, dosage fabrication and novel drug delivery systems which are carried out either in-house or in collaboration with Universiti Sains Malaysia and other tertiary institutions in the country.

Federation of Malaysian Manufacturers:
MOPI is an association member of the Federation of Malaysian Manufacturers (FMM) and in that capacity serves as the pharmaceutical industry's liaison with other industries.

ASEAN Pharmaceutical Club:
MOPI represents the Malaysian Pharmaceutical industry in the ASEAN Pharmaceutical Industry Club, an organisation which it had helped to form under the ASEAN Chamber of Commerce and Industry.

Chemical Industries Council of Malaysia (CICM):
MOPI is an honorary member of CICM Executive Committee.
International Medical University, Malaysia (IMU)
MOPI is a member of the Board of Studies - Bachelor of Pharmacy (Hons) of the lMU.
Parenteral Drug Association, USA
Member of Parenteral Drug Association, USA, an international association for pharmaceutical science and technology.

Dialogues with Minister of Health and National Pharmaceutical Control Bureau:
MOPI also holds regular dialogues with the Health Minister and the National Pharmaceutical Control Bureau to resolves issues affecting the industry.

Dialogues with Minister of International Trade & Industry:
Since 1984, MOPI has acted as representative for the Malaysian pharmaceutical industry in the annual dialogues with the Ministry of International Trade and Industry.

Dialogues with Minister of Domestic Trade & Consumer Affairs MOPI participates in the annual dialogue representing the industry on matters pertaining to intellectual property and consumer protection.

For more information contact:
GPE EXPO PVT. LTD.
GLOBAL, Opp. Priyadarshini Tower,
Near Judges' Bungalows,
Bodakdev, AHMEDABAD - 380 015. India
Tel.: +91.79.4000..8233 / 4000.8254
TeleFax: +91.79.4000.1390
E-mail: globaltouch@icenet.net ,globaltouch@indiatimes.com

ASIA Pharma Expo 2004 (APE2004), a three-day international exhibition, will be held at Mid Valley Exhibition Centre, Kuala Lumpur in Malaysia from April 21, 2004.

According to a press release received here, the exhibition, is exclusively focused towards pharmaceutical allied industries featuring pharma processing, packaging machinery and materials, biotechnology, alternative medicines, API, drug intermediates, healthcare products, environmental control equipments and services, analytical laboratory services and supplies, software for pharma industry and management trade publications, technical publications, trade associations, consultants, etc.

Bhullar, ABC Exhibitions, Malaysia, the Organiser of APE2004 informed that the event is the concurrent exhibition with the 9th Southeast Asia Healthcare Show, and being supported by Government, Trade Associations, and various Embassies, that include Ministry of Health, Malaysia Malaysian External Trade Development Corporation (MATRADE), Malaysian Industrial Development Authority (MIDA), Malaysian Organisation of Pharmaceutical Industries (MOPI), National Sports Institute, British High Commission, Kuala Lumpur, The American Embassy, Kuala Lumpur, Austrian Embassy Office of the Commercial Counselor, Embassy of Switzerland, Kuala Lumpur.
Reveling the importance about the APE2004, the first ever-international exhibition of Malaysia, Paresh Jhurmarwala, Global Pharma Expo, India and the Worldwide Sales Agent of APE2004 said, Malaysia presents the best opportunity for expansion in to SE-Asia with the market growth rate of 10 per cent for the pharma industry. The set-up of total 254 pharma formulation units accounting the estimated turnover: US$ 790 million Malaysia has become one of the first countries in the Association of Southeast Asia Nations (ASIAN) to gain the membership in Europe's Pharmaceutical Inspection Cooperation Scheme (PICS) in January 2002.

The recognition has enabled Malaysian pharma companies more easily to export their products to PICS members, mainly in the European Union.

Visitors expected include pharma, cosmetic, alternate medicine and food industry. International participation is expected at APE2004 from Pharma fraternities of countries like Singapore, Indonesia, Thailand, Philippines, Sri Lanka, India, and China. APE2004 offers the ideal opportunity to meet the decision makers of every discipline.
More information about APE2004 can be accessed from http://www.asiapharma.org the exhibition website or contact the Worldwide Sales Agent,
M/s. GPE EXPO PVT. LTD.
GLOBAL, Opp. Priyadarshini Tower,
Near Judges' Bungalows,
Bodakdev, AHMEDABAD - 380 015. India
Tel.: +91.79.4000..8233 / 4000.8254
TeleFax: +91.79.4000.1390
E-mail: globaltouch@icenet.net ,globaltouch@indiatimes.com

MALAYSIA is coming up with the first ever international exhibition on pharmaceutical industry. This trade show is to be held in conjunction with the 9th Southeast Asian Healthcare Show and Conference 2004.

The exhibition is supported by the government; trade bodies, the industry and the embassies will have pharma, cosmetic, alternative medicines food as categories. Along with Malaysia, China, India, Singapore, European Union, Indonasia, Thailand, Philippines, Taiwan, Korea, Shri Lanka etc., will be held during April 21-23,2004.

The exhibition targets to showcase the best in Pharma allied sector, packaging machinery, packaging materials, lab instruments & lab ware, APl, Drug intermediates, additives, excipients, biotechnology, environment control equipment & service.

WHY MALAYSIA?
Malaysia presents the best opportunity for expansion in to SE-Asia
The market growth rate of the Malaysian pharmaceutical industry is 10%
Total 254 pharma formulation units
Estimated turnover: US$790 million
Malaysia has become: one of the first countries in the Association of Southeast Asia Nations (ASEAN) to gain the membership in Europe's Pharmaceutical Inspection Cooperation Scheme: (P1CS) in January 2002. The recognition has enabled Malaysian pharma companies more easily to export their products to PIC/S members, mainly in the European Union.
Exhibition supported by the Government, Trade Associations, the Industry and the Embassies.

The Malaysian pharmaceutical market is worth USD 790 million and the growth rate is pegged at 8 to 10% per annum. There are total of 254 pharma formulation units and Malaysia has become one of the first countries in the Association of Southeast Asian Nations (ASEAN) to gain the membership in Europe's Pharmaceutical Inspection Co-operation Scheme (PIC/S) in January 2002. The recognition has enabled Malaysian pharma companies more easily to export their products to PIC/S members, mainly to the European Union. Against this backdrop, the event promises to be a mega show with international participation from countries like Singapore, Indonesia, Thailand, Philippines, Sri Lanka, India and China.

Mr Bhullar, ABC Exhibitions, Malaysia, Organizer of APE2004, informed that the event would be held concurrently with the 9th Southeast Asia Healthcare Show, and is supported by Government, Trade Associations, and various Embassies, that include Ministry of Health, Malaysia; Malaysian External Trade Development Corporation; Malaysian Industrial Development Authority; Malaysian Organization of Pharmaceutical Industries; National Sports Institute; British High Commission, Kuala Lumpur; The American Embassy, Kuala Lumpur; Austrian Embassy Office of the Commercial Counselor; Embassy of Switzerland, Kuala Lumpur; and Indian Drug Manufacturers Association to promote trade between the two countries.

About the activities of GPE, according to Mr Paresh Jhurmarwala, "We are a multifaceted organization and have established a respected image of Event Managers, Media Promotion Agency in the Indian pharmaceutical industry for National and International Industrial & Technical Periodicals. GPE is one of the founder member of IPMMA, has Associate Membership of India Trade Promotion Organization (ITPO), and Member of CHEMEXC1L. GFE had also successfully marketed the 53rd IPC-Pharma Expo 2001, New Delhi and IndiaChem 2000, New Delhi exhibitions, both organized by FICCl

MALAYSIA is likely to emerge as a leading destination for Indian pharma companies in the South East Asia as India and Malaysia have many similarities in terms of environment and labour culture, says Paresh Jhurmarvala, Founder and CEO of Global Pharma Expo, which is conducting Asia Pharma Expo - 2004, the first pharma expo in Malaysia from April 21-23, 2004. The event is being organized by ABC Exhibitions and Global Pharma Expo, and is supported by Ministry of Health, Malaysian Organization of Pharmaceutical Industries, etc. This is also the first overseas exhibition endorsed by IDMA.

Malaysia presents the best opportunity for expansion in South East Asia as the present $450 million market of that country is growing at a rate of 10 percent every year, and the market would grow to US$790 million in the next two years. Now only 254 pharma formulation units are active in Malaysia, and bulk drug manufacturing units are rare.